-22%

est. 2Y upside i

HealthcareSeries B

Rank

#2786

Sector

Oral Health & Personal Care

Est. Liquidity

~4Y

Data Quality

Data: Medium

Quip offers a moderate expected upside of -22% over 2 years, with high risk from a stale 2021 Series B valuation and significant preference overhang.

Last updated: July 21, 2026

Bull (25%)+56%

If Quip achieves IPO within 2 years, multiple holds at 6x on $78M revenue, giving $468M exit, 56% upside from $300M entry.

Base (50%)-22%

Multiple converges to public comps ~3x on $78M revenue, exit $234M, -22% downside.

Bear (25%)-100%

Multiple compresses to 2x on $78M revenue ($156M) below $162M preference stack, common stock worthless.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

54%

Total funding $162.2M vs estimated entry valuation $300M gives 54% preference overhang.

Dilution Risk

low

Company is profitable and cash flow positive, so no near-term dilution expected.

Secondary Liquidity

none

No secondary market activity reported.

View all 4 open roles at Quip →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Quip's data — designed to show you've done your homework.

  • 1

    “How does Quip plan to compete against incumbents like Oral-B and Sonicare in both product and services?”

  • 2

    “What is the company's path to IPO or acquisition given the current market?”

  • 3

    “Given the preference stack, how does the company plan to ensure employee equity has real value?”

Community

Valuation Sentiment

Our model estimates -22% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.